Voyager Therapeutics’ Directors Rush to Buy Options as Capital‑Raising Looms, Stirring Investor Confidence and Dilution Concerns
Voyager Therapeutics’ insider option surge signals executive confidence amid dilution risks; investors should weigh the gene‑therapy upside against potential share‑price pressure.
4 minutes to read
